Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/206891
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Intracellular delivery of an antibody targeting gasdermin-b reduces her2 breast cancer aggressiveness |
Autor: | Molina-Crespo, Ángela; Cadete, Ana; Sarrió, David CSIC ORCID; Gamez-Chiachio, Manuel CSIC ORCID; Martínez Sánchez, Lidia CSIC; Chao, Kinlin; Olivera, Ana; Gonella, Andrea; Díaz, Eva; Palacios, José; Dhal, Pradeep K.; Besev, Magnus; Rodríguez-Serrano, Macarena; García-Bermejo, María Laura; Triviño, Juan Carlos; Cano, Amparo CSIC; García-Fuentes, Marcos; Herzberg, Osnat; Torres, Dolores; Alonso, María José; Moreno-Bueno, Gema CSIC ORCID | Fecha de publicación: | 1-ago-2019 | Editor: | American Association for Cancer Research | Citación: | Clinical Cancer Research 25(15): 4846-4858 (2019) | Resumen: | [Purpose]: Gasdermin B (GSDMB) overexpression/amplification occurs in about 60% of HER2 breast cancers, where it promotes cell migration, resistance to anti-HER2 therapies, and poor clinical outcome. Thus, we tackle GSDMB cytoplasmic overexpression as a new therapeutic target in HER2 breast cancers. Experimental Design: We have developed a new targeted nanomedicine based on hyaluronic acid–biocompatible nanocapsules, which allow the intracellular delivery of a specific anti-GSDMB antibody into HER2 breast cancer cells both in vitro and in vivo. [Results]: Using different models of HER2 breast cancer cells, we show that anti-GSDMB antibody loaded to nanocapsules has significant and specific effects on GSDMB-overexpressing cancer cells' behavior in ways such as (i) lowering the in vitro cell migration induced by GSDMB; (ii) enhancing the sensitivity to trastuzumab; (iii) reducing tumor growth by increasing apoptotic rate in orthotopic breast cancer xenografts; and (iv) diminishing lung metastasis in MDA-MB-231-HER2 cells in vivo. Moreover, at a mechanistic level, we have shown that AbGB increases GSDMB binding to sulfatides and consequently decreases migratory cell behavior and may upregulate the potential intrinsic procell death activity of GSDMB. [Conclusions]: Our findings portray the first evidence of the effectiveness and specificity of an antibody-based nanomedicine that targets an intracellular oncoprotein. We have proved that intracellular-delivered anti-GSDMB reduces diverse protumor GSDMB functions (migration, metastasis, and resistance to therapy) in an efficient and specific way, thus providing a new targeted therapeutic strategy in aggressive HER2 cancers with poor prognosis. |
Descripción: | © 2019 American Association for Cancer Research. | Versión del editor: | http://dx.doi.org/10.1158/1078-0432.CCR-18-2381 | URI: | http://hdl.handle.net/10261/206891 | DOI: | 10.1158/1078-0432.CCR-18-2381 | ISSN: | 1078-0432 | E-ISSN: | 1557-3265 |
Aparece en las colecciones: | (IIBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
71
checked on 25-mar-2024
WEB OF SCIENCETM
Citations
72
checked on 26-feb-2024
Page view(s)
145
checked on 28-mar-2024
Download(s)
27
checked on 28-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.